Sofosbuvir D6
| Product Name | Sofosbuvir D6 |
|---|---|
| Alternate Names | Sofosbuvir Stable Isotopes, Stable Isotopes of Sofosbuvir |
| CAT No. | CS-O-10984 |
| CAS No. | 1868135-06-1 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 535.49 g/mol |
| Mol. For. | C₂₂H₂₃D₆FN₃O₉P |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Sofosbuvir |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | C[C@@]1([C@H](N(C=CC2=O)C(N2)=O)O[C@H](CO[P](OC3=CC=CC=C3)(N[C@@H](C)C(OC(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)=O)[C@H]1O)F |
| Canonical Smiles | CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 |
| InchIKey | TTZHDVOVKQGIBA-FMYNZQRGSA-N |
| Inchl | InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1/i1D3,2D3 |
| IUPAC | 1,1,1,3,3,3-hexadeuteriopropan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Sofosbuvir D6 is a deuterated analog of Sofosbuvir, a direct-acting antiviral drug used to treat hepatitis C virus (HCV) infection. The deuterium substitution provides improved pharmacokinetic properties, allowing for better absorption and distribution of the drug in the body. Sofosbuvir D6 works by inhibiting the RNA polymerase enzyme, which is essential for HCV replication, thus preventing the virus from reproducing and spreading in the body.
Sofosbuvir D6 is typically administered orally in the form of a tablet, with a recommended dosage of 400mg per day. The drug is commonly used in combination with other antiviral medications, such as ledipasvir or velpatasvir, to increase its effectiveness in treating HCV infection. Sofosbuvir D6 has been shown to have a high cure rate for HCV, with minimal side effects.
Chemically, Sofosbuvir D6 is a prodrug that is metabolized in the liver to its active form, GS-461203. The drug is primarily eliminated through the kidneys, and its half-life in the body is approximately 0.5 to 2 hours. Sofosbuvir D6 is a white to off-white powder that is soluble in water and ethanol.
In conclusion, Sofosbuvir D6 is an effective and safe medication used to treat HCV infection. Its deuterated structure provides improved pharmacokinetic properties, allowing for better absorption and distribution in the body. When used in combination with other antiviral medications, Sofosbuvir D6 has a high cure rate for HCV, making it an important tool in the fight against this disease.
Get an Instant Quote
Related Compounds
Sofosbuvir metabolite GS331007 13CD3 | Sofosbuvir metabolite GS-566500 13CD3 | Sofosbuvir Met. D-13C-15N2 | Sofosbuvir 13CD3 |